NF-κB as potential target in the treatment of melanoma

Gabriele Madonna, Claudio D. Ullman, Giusy Gentilcore, Giuseppe Palmieri, Paolo A. Ascierto

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.

Original languageEnglish
Article number53
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - 20 Mar 2012
Externally publishedYes

Fingerprint

Tumors
Melanoma
Signal transduction
Protein-Serine-Threonine Kinases
Proto-Oncogene Proteins B-raf
Neoplasms
Phosphotransferases
Chemical activation
Apoptosis
Signal Transduction
Mutation
Therapeutics

Keywords

  • Bortezomib
  • Curcumin
  • Melanoma
  • NBD peptide
  • Nf-κb

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

NF-κB as potential target in the treatment of melanoma. / Madonna, Gabriele; Ullman, Claudio D.; Gentilcore, Giusy; Palmieri, Giuseppe; Ascierto, Paolo A.

In: Journal of Translational Medicine, Vol. 10, No. 1, 53, 20.03.2012.

Research output: Contribution to journalReview article

Madonna, Gabriele ; Ullman, Claudio D. ; Gentilcore, Giusy ; Palmieri, Giuseppe ; Ascierto, Paolo A. / NF-κB as potential target in the treatment of melanoma. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{d7c84c05741145c9896834e8cb79f8c3,
title = "NF-κB as potential target in the treatment of melanoma",
abstract = "The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50{\%} of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.",
keywords = "Bortezomib, Curcumin, Melanoma, NBD peptide, Nf-κb",
author = "Gabriele Madonna and Ullman, {Claudio D.} and Giusy Gentilcore and Giuseppe Palmieri and Ascierto, {Paolo A.}",
year = "2012",
month = "3",
day = "20",
doi = "10.1186/1479-5876-10-53",
language = "English",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - NF-κB as potential target in the treatment of melanoma

AU - Madonna, Gabriele

AU - Ullman, Claudio D.

AU - Gentilcore, Giusy

AU - Palmieri, Giuseppe

AU - Ascierto, Paolo A.

PY - 2012/3/20

Y1 - 2012/3/20

N2 - The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.

AB - The RAS/MAP kinase pathway has attracted attention because activating mutations of the BRAF serine/threonine kinase was described in over 50% of melanomas. Very recently, selective and potent BRAF inhibitors have been developed. Several other signal transduction pathways have been found to be constitutively active or mutated in other subsets of melanoma tumors that are potentially targetable with new agents. Among these, NFκB is another pathway that melanoma tumors use to achieve survival, proliferation and resistance to apoptosis. Inhibition of NF-κB activation appears to be a very promising option for anti-cancer therapies.

KW - Bortezomib

KW - Curcumin

KW - Melanoma

KW - NBD peptide

KW - Nf-κb

UR - http://www.scopus.com/inward/record.url?scp=84858411005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858411005&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-53

DO - 10.1186/1479-5876-10-53

M3 - Review article

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 53

ER -